Tarsus Pharmaceuticals, Inc.
TARS
Rank in Stocks
#4704
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Share Price
$68.50
Last synced: 2026-10-16
Market Cap
$3.21B
Change (1 day)
-3.51%
Change (1 year)
-6.07%
Country
US
Trade Tarsus Pharmaceuticals, Inc. (TARS)
Category
Healthcare
EPS for Tarsus Pharmaceuticals, Inc. (TARS)
EPS as of June 2026 TTM: $-1.09
According to Tarsus Pharmaceuticals, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-1.09. At the end of 2023 the company had a EPS of $-4.62 an increase over its 2022 EPS that were of $-2.52.
EPS history for Tarsus Pharmaceuticals, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.09 | -64.50% |
| 2024 | $-3.07 | -33.55% |
| 2023 | $-4.62 | 83.33% |
| 2022 | $-2.52 | 276.12% |
| 2021 | $-0.67 | -49.24% |
| 2020 | $-1.32 | 450.00% |
| 2019 | $-0.24 | -22.58% |
| 2018 | $-0.31 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -1,688.99% |
US
|
|
| $-7.98 | 632.11% |
US
|
|
| $-5.29 | 385.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,644.95% |
NL
|
